

Special Issue

Exploring Metabolomics and Other Biomarkers for Osteosarcopenic Adiposity Detection, Prevention and Management

Message from the Guest Editor

The purpose of this Special Issue is to bring more insight into the metabolic nature of OSA by investigating the following:

1. Biomarkers for each tissue (bone, muscle, adipose) which, in combination, may indicate the existing impairments and presence of OSA, possibly discovering/identifying or proposing the series of omics.
2. In view of recent technological advances, such as genomic sequencing and molecular targeted drug exploitation, the concept of precision medicine can be used to demarcate OSA using multiple data sources from genomics to digital health metrics to artificial intelligence in order to facilitate an individualized yet “evidence-based” decisions regarding diagnostic and therapeutic approaches. In this way, therapeutics can be centered toward patients based on their molecular presentation rather than grouping them into broad categories with a “one size fits all” approach.
3. Any type of review or research article is welcome.

Guest Editor

Prof. Dr. Jasminka Ilich-Ernst
Institute for Successful Longevity, Florida State University, Tallahassee,
FL 32306, USA

Deadline for manuscript submissions

closed (31 May 2024)



Metabolites

an Open Access Journal
by MDPI

Impact Factor 4.5
CiteScore 8.1
Indexed in PubMed



mdpi.com/si/188916

Metabolites
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
metabolites@mdpi.com

[mdpi.com/journal/
metabolites](https://mdpi.com/journal/metabolites)





Metabolites

an Open Access Journal
by MDPI

Impact Factor 4.5
CiteScore 8.1
Indexed in PubMed



[mdpi.com/journal/
metabolites](https://mdpi.com/journal/metabolites)



About the Journal

Message from the Editor-in-Chief

The metabolome is the result of the combined effects of genetic and environmental influences on metabolic processes. Metabolomic studies can provide a global view of metabolism and thereby improve our understanding of the underlying biology. Advances in metabolomic technologies have shown utility for elucidating mechanisms which underlie fundamental biological processes including disease pathology. *Metabolites* is proud to be part of the development of metabolomics and we look forward to working with many of you to publish high quality metabolomic studies.

Editor-in-Chief

Dr. Amedeo Lonardo
Internal Medicine, Ospedale Civile di Baggiovara, Azienda Ospedaliero-
Universitaria, 41126 Modena, Italy

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Biochemistry and Molecular Biology) / CiteScore - Q1 (Endocrinology, Diabetes and Metabolism)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 16.7 days after submission; acceptance to publication is undertaken in 3.6 days (median values for papers published in this journal in the second half of 2025).